Experience with modified radical mastectomy in a low-income country: a multi-center prospective observational study

Giziew Bawoke, Segni Kejela*, Abebe Alemayehu and Girmaye Tamirat Bogale

Abstract
Background: Modified radical mastectomy is the procedure of choice in centers with little to no radiotherapy services. Studying the in-hospital outcome and complications associated with the procedure is important in low-income countries.

Methods: This is a multi-center prospective observational study involving all patients operated with modified radical mastectomy with curative intent.

Results: A total of 87 patients were studied with 10.3% of which were male and 54% were between the age of 30–49 years. Clinical stage IIB and IIIA were reported in 33 (37.9%) and 25 (28.7%) respectively and 62.1% had clinically positive lymph nodes at presentation. All of the studied patients underwent curative surgery, with an average lymph node dissection of 10.2 ± 0.83. Seroma rate was 17.2% and was significantly associated with diabetes (AOR: 6.2 (CI 1.5–8.7)) and neoadjuvant chemotherapy (AOR: 8.9 (CI 1.2–14.2)). Surgical site infection occurred in 14.9% and was significantly associated with Retroviral infections (AOR: 4.2 (CI 2.1–5.8)) and neoadjuvant chemotherapy (AOR: 1.8 (CI 1.3–3.9)). No in-hospital mortality occurred during the course of the study.

Conclusion: Seroma rate was lower than published studies while surgical site infections rate was higher. Neoadjuvant chemotherapy was associated with increase in seroma and surgical site infection rates. Additionally, diabetes increased the rate of seroma. Surgical site infections were higher in patients with retroviral infections.

Keywords: Modified radical mastectomy, Early postoperative complications, Neoadjuvant chemotherapy, Breast cancer

Introduction
The low and middle income countries are responsible for more than 60% of breast cancer related global annual mortality. This burden is even more pronounced in Sub-Saharan Africa [1, 2]. In Ethiopia, as in all Sub-Saharan nations, breast cancer is a concerning public health problem, contributing to more than 30% of cancer diagnosis in women [3].
breast-conserving surgeries and instead perform mastectomy to avoid the need for radiation therapy in most patients regardless of the stage at diagnosis [11].

The lack of available radiotherapy facilities and advanced stage of patients at presentation have made mastectomy the preferred surgery in Ethiopia. Hence, it is imperative to study the in-hospital outcomes of mastectomy in a low-income country to assess its safety with regards to short term complications, and efficacy with regards to the status of oncologic resection.

Methods

Study setting
This study was done in four tertiary teaching hospitals in the capital city, Addis Ababa, Ethiopia. The hospitals were Tikur Anbessa Specialized Hospital, Zewditu Memorial Hospital, Yekatit 12 Memorial Hospital and Minilik II Memorial Hospital. These hospitals serve populations both from Addis Ababa and regional states with sub-speciality level surgical service.

Study design and population
This is a multi-institutional prospective observational study of in-hospital outcomes and complications of patients undergoing Modified radical mastectomy. The study population was all patients undergoing Modified radical mastectomy for curative intent operated during the study period (July 1, 2019, to September 30, 2020) at the four hospitals. All patients undergoing palliative mastectomy and radical mastectomy were excluded from this study.

Study variables
Independent variables were age, sex, residence, smoking history, comorbidities, body mass index, histologic type, clinical-stage, history of neoadjuvant therapy, level of lymph node dissection, number of positive lymph nodes, and history preoperative prophylactic antibiotics.

Dependent variables were rate of seroma, surgical site infections, hematoma, skin flap necrosis, and perioperative mortality rate.

Data collection and analysis
Data from the patients were collected using a structured format filled during their in-hospital stay prospectively. All complications were daily evaluated and recorded.

Completeness of the data was assured at each step and entered into the SPSS version 23. Initial descriptive analysis was done for socio-demographic and clinical variables in the study with mean, median, range, and frequency. Then inferential analysis was done using Student t-test and Chi-square depending on the type of the variable, and values in univariable regression found to be less than 0.2 were evaluated in multivariable regression.

Outcomes
Primary outcomes were the rates of surgical complications such as, seroma, surgical site infections, wound dehiscence, skin flap necrosis and hematoma formation. In addition, associations between preoperative comorbidities, with postoperative complications were assessed.

Secondary outcomes were rate of complete pathologic resection, lymph node harvest rate, level of lymph node dissection, drainage tube removal and length of hospital stay.

Surgical procedure
The “modified radical mastectomy” procedure done according to the standard recommendations in all study centers. In all patients, elliptical incisions surrounding the nipple-areola complex were made. Then skin flap was raised in the superior direction to the level of the clavicle and in the inferior aspect to the level of the inframammary fold. The Pectoralis fascia was raised from the underlying pectoralis muscle completely. The axilla was dissected in levels I and II in all patients. Optional level III dissection was done where there was bulky level II lymphadenopathy or any level III lymphadenopathy. The drain was placed within 2 cm of the surgical wound margin and the wound was closed primarily. The number of drains used (mostly 2) and the method of wound closure were left to the discretion of the operating surgeon. All specimens were subjected to pathology evaluation. There was no single case of immediate breast reconstruction.

Ethical considerations
Ethical approval was gained from the Institutional Review Board of Addis Ababa University, College of Health Sciences, which is the governing body of health researches under Addis Ababa University. The approval letter was disseminated to all affiliated hospitals for the study and each hospital involved in the study provided approval for the data collection. The study was conducted in accordance to Helsinki declarations, Ethiopian National Research Ethics Guidelines, and Institutional regulations on research ethics.

All participants of the study provided signed written informed consent before initiation of the data collection. All data collected from the patients were kept confidential. No individual outside of the authors had any access to the patients’ information.

Funding and conflict of interest
Funding for this study was acquired from Addis Ababa University, College of health sciences. Funder had no
contribution to the study design, study conduct or manuscript preparation, and had no say on conclusion and dissemination of results.

Results

Sociodemographic factors of the patients

A total of 87 consecutive patients were evaluated during the course of the study of which 78 (89.7%) were females. The most common age groups were 30–39 years and 40–49 years with 24 (27.6%) and 23 (26.4%) respectively, and a mean age of 45.6 ± 12.5 years. 70 (80.5%) of the patients were from the capital, Addis Ababa, while the rest were from regional states. Hypertension and retroviral infections were the most common comorbidities, with 12 (13.8%) and 10 (11.5%) respectively. 2 (2.3%) of the patients were obese (BMI > 30 kg/m²), while 4 (4.6%) were found to have moderate to severe under-nutrition (BMI < 17 kg/m²). 17 (19.5%) of the patients had neoadjuvant chemotherapy (Table 1).

Cancer characteristics and surgery

With regards to the clinical T stage of the patients, T2 and T3 were the most common tumor stages at 31 (35.6%) and 37 (42.5%) respectively, while T1 and T4 were the least common, contributing to 5 (5.7%) and 14 (16%) respectively, while. At the time of admission for surgery, 54 (62.1%) of the patients had clinically positive lymph nodes (Table 1). The most common stages at diagnosis were AJCC 8 clinical-stage IIB and IIIA at 33 (37.9%) and 25 (28.7%) respectively. Stage IA and IIIC were the least common with 1 patient in each stage. (Fig. 1) Sixteen (94.1%) of the 17 patients residing outside of the capital

Table 1  Sociodemographic and surgical factors of the patients with modified radical mastectomy at four teaching hospitals, Addis Ababa, Ethiopia (n = 87)

| No | Variables                        | Category                        | Number | Percentage (%) |
|----|----------------------------------|---------------------------------|--------|----------------|
| 1  | Sex                              | Male                            | 9      | 10.3           |
|    |                                  | Female                          | 78     | 89.7           |
| 2  | Age (years)                      | 24–29                           | 8      | 9.2            |
|    |                                  | 30–39                           | 24     | 27.6           |
|    |                                  | 40–49                           | 23     | 26.4           |
|    |                                  | 50–59                           | 21     | 24.1           |
|    |                                  | 60–69                           | 4      | 4.6            |
|    |                                  | 70–79                           | 7      | 8              |
| 3  | Residence                        | Addis Ababa                     | 70     | 80.5           |
|    |                                  | Regional states                 | 17     | 19.5           |
| 4  | Comorbidities                    | Hypertension                    | 12     | 13.8           |
|    |                                  | Diabetes mellitus               | 7      | 8              |
|    |                                  | Retroviral infection            | 10     | 11.5           |
|    |                                  | Others                          | 4      | 4.6            |
| 5  | Body Mass index(kg/m²)           | > 30                             | 2      | 2.3            |
|    |                                  | 24–29.9                         | 6      | 6.9            |
|    |                                  | 17–23.99                        | 75     | 81.6           |
|    |                                  | < 17                            | 4      | 4.6            |
| 6  | Preoperative treatment           | Neoadjuvant chemotherapy        | 17     | 19.5           |
|    |                                  | Without neoadjuvant chemotherapy| 70     | 80.5           |
| 7  | Clinical tumor stage             | T1                              | 5      | 5.7            |
|    |                                  | T2                              | 31     | 35.6           |
|    |                                  | T3                              | 37     | 42.5           |
|    |                                  | T4                              | 14     | 16             |
| 8  | Lymph node status                | Negative                        | 33     | 37.9           |
|    |                                  | Positive                        | 54     | 62.1           |
| 9  | Level of Lymph node dissection   | Level I and II                  | 84     | 96.6           |
|    |                                  | Level I–III                     | 3      | 3.4            |
| 10 | Number of lymph nodes harvested  | ≥ 10                            | 45     | 51.7           |
|    |                                  | < 10                            | 42     | 48.3           |
city had stage III disease, compared to 23 (32.8%) of the 70 patients from Addis Ababa. Compared to 8 (88.9%) of the 9 male patients with stage III disease, 31 (39.7%) of the 78 of all the female patients had stage III disease at diagnosis. All patients had preoperative histologic diagnosis. Ductal carcinoma was reported in 79 (90.8%), and lobular carcinoma in 5 (5.7%). 3 (3.4%) patients had no specific histologic subtype reported.

During surgery, prophylactic preoperative antibiotics were avoided in all patients. All underwent curative surgery with pathologically confirmed clear tumor margins, and with level I and II lymph node dissection in 84 (96.6%), and level I–III in the remaining group of patients. The average number of lymph nodes retrieved were 10.2 ± 0.83 with a range of 2–19. 45 (51.7%) patients had 10 or more lymph nodes harvested. The average number of pathologically positive lymph nodes was 4.71 ± 0.71 with a range of 0–14. At the completion of the surgery, all patients had drainage tubes placed which was removed, on average, on postoperative day 5 with a range of 3–17 days.

Postoperative complications and regression analysis
Postoperatively, 25 (28.7%) of the patients had one or more complications. The overall incidence of seroma, the most common postoperative complication, was 15 (17.2%). The rate of surgical site infections was 13 (14.9%). Hematoma and wound dehiscence occurred in 4 (4.6%) and 6 (6.9%) patients respectively. 1 patient had skin flap necrosis (Fig. 2).

In the regression analysis, seroma was positively associated with diabetes (p-value: 0.001), history of neoadjuvant chemotherapy (p-value: 0.006), 10 or more lymph nodes harvested (p-value: 0.006), Body Mass Index of ≥ 24 kg/m² (p-value: 0.001) on the univariable analysis. On multivariable analysis, diabetes (AOR: 6.2 (1.5–8.7), p-value: 0.043) and neoadjuvant chemotherapy (AOR: 8.9 (1.2–14.2), p-value 0.035) were statistically significant in their association with seroma. The number of lymph nodes harvested and BMI had a trend towards statistical significance (AOR: 1.5 (1.11–3.1), p-value: 0.10, and AOR: 1.4 (1.2–2.3), p-value: 0.14 respectively) (Table 2). Univariable analysis showed retroviral infections (RVI) (p-value: 0.001), cigarette smoking (p-value: 0.041) and neoadjuvant chemotherapy (p-value: 0.014), level III lymph node dissection (p-value: 0.041) and presence of seroma (p-value: 0.037) to be positively associated with surgical site infections. On multivariable analysis, RVI (AOR: 4.2 (2.1–5.8), p-value: < 0.001) and history of neoadjuvant chemotherapy (AOR: 1.8 (1.3–3.9), p-value: 0.026) were found to be statistically significant (Table 3). No mortality was reported among the study group during the in-hospital course of the patients.

Discussion
As far as we know this prospective study is the first of its kind to study early post mastectomy complications in Ethiopia. In this study, just more than 10% of the patients were males and more than 50% were among the age group 30–49 years. Hypertension and RVI were the most commonly reported comorbidities, and two-thirds of the patients had stage IIB and IIIA disease. Level I and II lymph node dissection was performed in more than 96% of the patients. 28.7% of the patients had at least one postoperative complication with seroma and surgical site infections being the most commonly reported complications. Patients with a history of neoadjuvant chemotherapy had 8.9 times higher rate of seroma and 1.8 times higher rate of surgical site infections compared to the up-front surgery group. Diabetes was associated with an increase in seroma rate by more than sixfold. Patients with retroviral infection had 4.2 times higher risk of surgical site infection.
Breast cancer in Ethiopia has consistently been shown to be associated with advanced stage at diagnosis [4, 7, 11]. Concordant reports have been published from other low-income countries [12–14]. Even in a study like ours where only patients with loco-regional disease were included, the proportion of early local stage like stage I is still extremely small. Lack of national screening programs, among other factors, may have contributed to the delay in diagnosis with resultant advanced stage at presentation in low income setups [15]. Published studies have confirmed that advanced stage at diagnosis and lack of appropriate treatment options were the main contributors to the disproportionately high rate of mortality from breast cancer in developing countries [15, 16].

This study found an enigma concerning the association between breast cancer and retroviral infections. In contrast to published bodies of literature reporting lower or equivalent breast cancer rate in patients with retroviral infection compared to general population, our study found that the proportion of breast cancer patients with retroviral infection exceeded 10%, which is far more than the rate of retroviral infections in the capital, 3.4% [17, 18]. We understand that the study was not designed to answer this question. Nonetheless, both population retroviral seropositivity rate and association between breast cancer and retroviral infections need reevaluation.

In our study, no prophylactic antibiotics was used and postoperatively, drainage tube was removed on the 5th postoperative day. Avoidance of prophylactic antibiotics for mastectomy, and drain removal on postoperative day 5 instead of on earlier days, are both supported by the current pieces of evidence [19, 20]. The level of lymph node dissections required during axillary lymph node dissection is set by the NCCN as level I and II anatomical regions of lymph nodes, and 10 lymph node numbers [21]. In our study, we were able to confirm that all patients underwent at least level I and II lymph node dissections and the average number of lymph nodes retrieved were 10.

The rate of seroma for mastectomy patients in other studies has been reported to range between 3 and 85% with an average of 39%, which is higher than the result we have found in our study, which was 17.2% [22, 23]. On the contrary, the rate of surgical site infections, 14.9% in our study, was higher in our patient population compared to published reports which ranged between 2 and 6% [24–26].

**Table 2** Factors associated with seroma

| No | Variables   | Category | Seroma rate (%) | p-value (univariable analysis) | AOR | p-value |
|----|-------------|----------|----------------|-------------------------------|-----|---------|
|    |             |          | Seroma No seroma |                                |     |         |
| 1  | Diabetes    | Yes      | 6 (85.7) 1 (14.3) | 0.001                         | 6.2 (1.5–8.7) | 0.043 |
|    |             | No       | 9 (11.2) 71 (88.8) |                              |     |         |
| 2  | Neoadjuvant | Yes      | 7 (41.2) 10 (58.8) | 0.006                         | 8.9 (1.2–14.2) | 0.035 |
|    |             | No       | 8 (11.4) 62 (88.6) |                              |     |         |
| 3  | LN harvest  | ≥ 10 LN  | 14 (31.1) 31 (68.9) | 0.006                         | 1.5 (1.11–3.1) | 0.10  |
|    |             | < 10 LN  | 1 (2.4) 41 (97.6)  |                              |     |         |
| 4  | BMI         | ≥ 24 kg/m² | 7 (87.5) 1 (12.5) | <0.001                        | 1.4 (1.2–2.3) | 0.14  |
|    |             | < 24 kg/m² | 8 (10.1) 71 (89.9) |                              |     |         |

LN lymph nodes, AOR adjusted odds ratio, BMI Body Mass Index

**Table 3** Factors associated with surgical site infections

| No | Variables   | Category | SSI rate (%) | p-value (univariable analysis) | AOR | p-value |
|----|-------------|----------|--------------|-------------------------------|-----|---------|
|    |             |          | SSI No SSI   |                                |     |         |
| 1  | RVI         | Yes      | 8 (80) 2 (20) | 〈0.001                        | 4.2 (2.1–5.8) | 〈0.001 |
|    |             | No       | 5 (6.5) 72 (93.5) |                              |     |         |
| 2  | Neoadjuvant | Yes      | 6 (35.3) 11 (64.7) | 0.014                         | 1.8 (1.3–3.9) | 0.026 |
|    |             | No       | 7 (10) 63 (90)  |                              |     |         |
| 3  | LN level    | I–III    | 2 (66.7) 1 (33.3) | 0.06                          | 1.16 (1.03–2.5) | 0.10  |
|    |             | I and II | 11 (13.1) 73 (86.9) |                              |     |         |

RVI Retroviral infection, LN lymph nodes, SSI surgical site infections, AOR adjusted odds ratio
Reports indicated older age, Hypertension, high volume of drainage output, serum protein concentration, longer operative time, and lack of patient-controlled analgesia to be risk factors for seroma formation [23, 27–29]. In contrast, in our study, we found a higher seroma rate in patients with a history of diabetes, neoadjuvant chemotherapy, 10 or more lymph node dissection and a higher BMI (> 24 kg/m²). Increase in seroma rate in patients treated with neoadjuvant chemotherapy has been reported before [29]. Similarly, the association between a higher BMI and seroma formation has been confirmed in published studies [29, 30]. Likewise, the number of lymph nodes retrieved in mastectomy is reported to be directly associated with rate of seroma formation. This is further affirmed by the report showing lower rate of seroma formation in patients undergoing sentinel lymph node biopsies compared to lymph node dissections [29, 31, 32]. But the association between seroma and diabetes found in our study, is not replicated in any other publication, and requires further study.

We found surgical site infections to be higher in patients treated with neoadjuvant chemotherapy and patients with retroviral infections. The association between RVI and surgical site infections has been reported for patients in orthopedics surgery even though the evidence was not robust [33]. One matched study for major general, orthopedic and gynecologic procedures failed to show an increase in postoperative complications rate except in patients with low CD4 count (50/μL) and high viral load (30,000 c/mL), which showed trends towards statistical significance [34]. In breast cancer surgery, we are not aware of any report on the association between surgical site infection and retroviral infections. Similarly, neoadjuvant chemotherapy has been shown to increase wound complications only in cohort of patients with mastectomy and immediate breast reconstruction [35]. Another review showed an increase in surgical site infections in the adjuvant chemotherapy group compared to neoadjuvant and no systemic therapy group in patients undergoing mastectomy with immediate breast reconstruction [36]. Another study has also disputed any increase in surgical site infections in patients with a history of neoadjuvant chemotherapy in patients with no immediate breast reconstruction [37]. Our finding stands in sharp contrast to available western evidence regarding neoadjuvant chemotherapy. With respect to association between RVI and surgical site infections, Ethiopian seropositive patients are shown to have a higher rate of nutritional deficiencies, higher viral load, and lower CD4 count relative to the western patients [38]. We suspect that the level of immunocompromisation of our patient population might have contributed to the higher rate of surgical site infections. Our study couldn’t establish any association between seroma formation and surgical site infections.

Strengths of this study include, its prospective design and multi-center involvement. The limitations of this study were, lack of further followup for delayed complications like upper extremity lymphedema. Smaller sample size due to a shorter study time of only 14 months can be added as another limitation. Finally, larger sample size and longer study should be conducted to evaluate both short and long term complications of mastectomy. In addition, a study is required to identify the cause for higher rate of surgical site infections.

Conclusion
Our finding showed that, even though the rate of seroma formation was lower than previous reports, surgical site infections rate was higher than previous studies. History of neoadjuvant chemotherapy was associated with increased seroma and surgical site infection rate. Furthermore, Diabetes, BMI ≥ 24 kg/m² and ≥ 10 lymph node harvested increased the rate of seroma. Surgical site infections were higher in patients with retroviral infections and level III lymph node dissections.

Abbreviations
AOR: Adjusted odds ratio; BMI: Body Mass Index; CD4: Cluster of differentiation 4; HIV/AIDS: Human immunodeficiency virus/acquired immunodeficiency syndrome; RVI: Retroviral infection; SPSS: Statistical Package for the Social Sciences.

Acknowledgements
We would like to extend our gratitude to the administrative and clinical staff of all the four teaching hospitals where the study was conducted in. We also would like to thank the department of surgery at Addis Ababa University for funding the study.

Authors’ contributions
GB: wrote the proposal for the research, data collection, analysis and wrote the manuscript. GTB participated in proposal and manuscript writing. AA: worked part of the manuscript. SK: conducted part of the analysis and wrote the manuscript.

Funding
Funding for this study was acquired from Addis Ababa University, College of health sciences. A total of 568 US dollars was provided from the university. Funder had no contribution to the study design, study conduct or manuscript preparation, and had no say on conclusion and dissemination of results.

Availability of data and materials
The data and material for this study would be provided with reasonable request to the corresponding author.

Declarations
Ethics approval and consent to participate
Ethical approval was gained from the Institutional Review Board of Addis Ababa University, College of Health Sciences, which is the governing body of health researches under Addis Ababa University. Subsequently, the approval letter was disseminated to all affiliated hospitals for the study and each hospital involved in the study provided approval was obtained. The study was
References

1. Shulman LN, Willett W, Sievers A, Knaul FM. Breast cancer in developing countries: opportunities for improved survival. J Oncol. 2010. https://doi.org/10.1155/2010/595167.

2. Azubuike SO, Murhead C, Hayes L, McNally R. Rising global burden of breast cancer: the case of sub-Saharan Africa (with emphasis on Nigeria) and implications for regional development: a review. World J Surg Oncol. 2018;16(1):1–13. https://doi.org/10.1186/s12957-018-1345-2.

3. Ethiopia: Global Cancer Observatory. International agency for research on cancer. WHO. Published in March 2021.

4. Tesfaw A, Demis S, Muniye T, Ashuro Z. Patient delay, and contributing factors among breast cancer patients at two cancer referral centres in Ethiopia: a cross-sectional study. J Multidiscip Healthc. 2020;13:1391–401.

5. Espina C, McKenize F, Dos-Santos-Silva I. Delayed presentation and diagnosis of breast cancer in African women: a systematic review. Ann Epidemiol. 2017;27(10):659-671.e7. https://doi.org/10.1016/j.annepidem.2017.09.007.

6. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313(2):165–73. https://doi.org/10.1001/jama.2014.17322.

7. Deressa BT, Cihoric N, Badra EV, et al. Breast cancer care in northern Ethiopia—a cross-sectional analysis. BMC Cancer. 2019;19:393. https://doi.org/10.1186/s12885-019-5612-6.

8. Grover S, Xu MJ, Yeager A, et al. A systematic review of radiotherapy capacity in low- and middle-income countries. Front Oncol. 2015;4:380. https://doi.org/10.3389/fonc.2014.00380.

9. Ethiopia makes progress in cancer treatment provision. World Nuclear News. https://world-nuclear-news.org/Articles/Ethiopia-makes-progress-in-cancer-treatment-provision. Accessed on 28th Aug 2021.

10. World population: Ethiopia. https://www.worldometers.info/world-population/ethiopia-population/. Accessed on 1st Sept 2021.

11. Abebe E, Demilie K, Lemmu B, Abebe K. Female breast cancer patients, mastectomy-related quality of life: experience from Ethiopia. Int J Breast Cancer. 2020.2020:8460374. https://doi.org/10.1155/2020/8460374.

12. Jedy-Agba E, McCormack V, Olomol O, et al. Determinants of the stage at diagnosis of breast cancer in Nigerian women: sociodemographic, breast cancer awareness, health care access and clinical factors. Cancer Causes Control. 2017;28(7):685–97. https://doi.org/10.1007/s10552-017-0894-y.

13. Wakanga W, Wisake R, Saidi H. A profile of female breast cancer patients in a Kenyan Urban Private Hospital. Ann Afr Surg. 2013;10(1):3–8.

14. Small F, Boudjella A, Dib A, Braikia S, Zidane H, Riggaad R, et al. Epidemiology of breast cancer in women based on diagnosis data from oncologists and senologists in Algeria. Cancer Treat Res Commun. 2020;25:100220. https://doi.org/10.1016/j.ctarc.2020.100220.

15. Black E, Richmond R. Improving early detection of breast cancer in sub-Saharan Africa: why mammography may not be the way forward. Glob Health. 2019;15:3. https://doi.org/10.1186/s12992-018-0446-6.

16. Donkor A, Lathlean J, Waiye J. Factors contributing to late presentation of breast cancer in Africa: a systematic literature review. Arch Med. 2015;8(2):1–10.

17. Chirkut S. Breast cancer, human immunodeficiency virus and highly active antiretroviral treatment: implications for a high-rate seropositive region. Oncol Rev. 2019;13(1):376. https://doi.org/10.4081/oncol.2019.376.

18. Kibret GD, Ferede A, Leshargie CT, et al. Trends and spatial distributions of HIV prevalence in Ethiopia. Infect Dis Poverty. 2019;8:90. https://doi.org/10.1186/s40249-019-0594-9.

19. Baghaki S, Soybir GR, Soran A. Guideline for antimicrobial prophylaxis in breast surgery. J Breast Health. 2014;10(2):79–82. https://doi.org/10.5152/jbsh.2014.1959.

20. Barton A, Blitz M, Callahan D, Yaksims W, Adams D, Daibbs K. Early removal of postmastectomy drains is not beneficial: results from a halted randomized controlled trial. Am J Surg. 2006;191(5):652–6. https://doi.org/10.1016/j.amjsurg.2006.01.037.

21. NCCN clinical practice guidelines in oncology: breast cancer. Version 5. 2021. www.NCCN.org.

22. Srivastava V, Baru S, Shukla VK. Seroma formation after breast cancer surgery: what we have learned in the last two decades. J Breast Cancer. 2012;15(4):373–80.

23. Hashemi E, Kaviani A, Najafi M, Ebrahim M, Hooshmand H, Montazeri A. Seroma formation after surgery for breast cancer. World J Surg Oncol. 2004;9(2):44. https://doi.org/10.1186/1477-7819-4-44.

24. Palubicka A, Jaworski R, Wekwej M, et al. Surgical site infection after breast surgery: a retrospective analysis of 5-year postoperative data from a single center in Poland. Medicina (Kaunas). 2019;55(9):512. https://doi.org/10.20516/medicina.55090512.

25. Omar AA, Al-Moussa HH. Surgical site infection complicating breast cancer surgery in Kuwait. Int Sch Res Notices. 2013. https://doi.org/10.1155/2013/295783.

26. Olsen MA, Nickel KB, Ida K. Incidence of surgical site infection following mastectomy with and without immediate reconstruction using private claim data. Infect Control Hosp Epidemiol. 2015;36(8):907–14. https://doi.org/10.1017/ice.2015.108.

27. Rizvi FH, Khan MK, Almas T, et al. Early postoperative outcomes of breast cancer surgery in a developing country. Cureus. 2020;12(8):e9941. https://doi.org/10.7759/cureus.9941.

28. Pan XF, Huan JL, Qin JX. Potential risk factors for the development of seroma following mastectomy with axillary dissection. Mol Clin Oncol. 2015;3(1):222–6. https://doi.org/10.3892/mco.2014.430.

29. Ziebiński J, Jaworski R, Irga N, Kruszewski JW, Jaskiewicz J. Analysis of selected factors influencing seroma formation in breast cancer patients undergoing mastectomy. Arch Med Sci. 2013(1):86–92. https://doi.org/10.1515/ams.2012.29219.

30. Garzali IU, El-Yakub AI. Factors affecting seroma formation after mastectomy. World J Surg Oncol. 2020.3.174.24567.

31. Srivastava V, Baru S, Shukla VK. Seroma formation after breast cancer surgery in a developing country. Cureus. 2020;12(8):e9941. https://doi.org/10.7759/cureus.9941.

32. Bijek JH, Aucouturier JS, Doridot V, Ghemari T, Nos C. Lymphocèles auxiliaires après curage ou prélèvement du ganglion sentinelle en cas de cancer du sein [Auxiliary lymphocele after axillary dissection or sampling of sentinel lymph node in breast cancer]. Bull Cancer. 2005;92(2):179–83.

33. Kigera JWM, Straetemans M, Vuhaka SK, Magel IM, Nadzumbua EU, Boer K. Is there an increased risk of postoperative surgical site infection after orthopedic surgery in HIV patients? A systematic review and meta-analysis. East Afr Orthop J. 2012;6(2):67–79.

34. Horberg MA, Hurley LB, Klein DB, et al. Surgical outcomes in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Arch Surg. 2006;141(12):1238–45. https://doi.org/10.1001/archsurg.141.12.1238.

35. Decker MR, Greenblatt DY, Havlena J, Wilkie LG, Greenberg CC, Neuman HB. Impact of neoadjuvant chemotherapy on wound complications after breast surgery. Surgery. 2012;152(3):382–8. https://doi.org/10.1016/j.surg.2012.05.001.

36. Pelded WA, Itakura K, Foster RD, et al. Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction. Arch Surg. 2010;145(9):880–5. https://doi.org/10.1001/archsurg.2010.163.
37. Chattha AS, Cohen JB, Bucknor A, et al. Surgical site infection in immediate breast reconstruction: does chemotherapy timing make a difference? J Surg Oncol. 2018;117(7):1440–6.
38. Assen A, Molla F, Wondimu A, et al. Late presentation for diagnosis of HIV infection among HIV positive patients in South Tigray Zone, Ethiopia. BMC Public Health. 2016;16:558. https://doi.org/10.1186/s12889-016-3263-y.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.